Table 1 Baseline characteristics of all patients in the study and control groups
Study group | Control group | p-value | |
|---|---|---|---|
n = 257 | n = 168 | ||
Sex n (%) | 0.901 | ||
Female | 153 (59.5) | 99 (58.9) | |
Male | 104 (40.5) | 69(41.1) | |
Age (years) median (min–max) | 65 (19–89) | 65 (30–89) | 0.864 |
Cancer, n (%) | < 0.001 | ||
Breast | 60 (23.3) | 67 (39.9) | |
Colorectal | 39 (15.2) | 35 (20.8) | |
Upper GI | 40 (15.6) | 20 (11.9) | |
Urogenital | 13 (5.1) | 27 (16.1) | |
Haematologic cancer | 56 (21.8) | 0 (0) | |
Others | 26 (10.1) | 19 (11.3) | |
Gyn | 23 (8.9) | 0 (0) | |
Treatment strategy, n (%) | 0.182 | ||
Adjuvant | 147 (57.2) | 107 (63.7) | |
Palliative | 110 (42.8) | 61 (36.3) |